Challenges and obstacles of ocular pharmacokinetics and drug delivery.

Modern biological research has produced increasing number of promising therapeutic possibilities for medical treatment. These include for example growth factors, monoclonal antibodies, gene knockdown methods, gene therapy, surgical transplantations and tissue engineering. Ocular application of these possibilities involves drug delivery in many forms. Ocular drug delivery is hampered by the barriers protecting the eye. This review presents an overview of the essential factors in ocular pharmacokinetics and selected pharmacological future challenges in ophthalmology.

[1]  A. Urtti,et al.  Systemic absorption of ocular pilocarpine is modified by polymer matrices , 1985 .

[2]  Bin Wang,et al.  Pegaptanib for the treatment of age-related macular degeneration. , 2006, Experimental eye research.

[3]  J. Robinson,et al.  Mechanistic studies on transcorneal permeation of pilocarpine. , 1976, Journal of pharmaceutical sciences.

[4]  A. Urtti,et al.  Vitreous Is a Barrier in Nonviral Gene Transfer by Cationic Lipids and Polymers , 2003, Pharmaceutical Research.

[5]  R. Schoenwald,et al.  Corneal penetration behavior of beta-blocking agents II: Assessment of barrier contributions. , 1983, Journal of pharmaceutical sciences.

[6]  A. Urtti,et al.  Controlled Ocular Timolol Delivery: Systemic Absorption and Intraocular Pressure Effects in Humans , 1994, Pharmaceutical Research.

[7]  Rupak K Banerjee,et al.  Evaluation of coupled convective-diffusive transport of drugs administered by intravitreal injection and controlled release implant. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[8]  A. Urtti,et al.  Permeability of retinal pigment epithelium: effects of permeant molecular weight and lipophilicity. , 2005, Investigative ophthalmology & visual science.

[9]  M. Prausnitz,et al.  Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye. , 1998, Journal of pharmaceutical sciences.

[10]  A. Urtti,et al.  Controlled drug delivery devices for experimental ocular studies with timolol 2. Ocular and systemic absorption in rabbits , 1990 .

[11]  H F Edelhauser,et al.  Drug delivery for posterior segment eye disease. , 2000, Investigative ophthalmology & visual science.

[12]  Juergen Siepmann,et al.  Sustained release of nanosized complexes of polyethylenimine and anti-TGF-beta 2 oligonucleotide improves the outcome of glaucoma surgery. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[13]  K Miyamoto,et al.  Transscleral delivery of bioactive protein to the choroid and retina. , 2000, Investigative ophthalmology & visual science.

[14]  H F Edelhauser,et al.  Transscleral drug delivery for posterior segment disease. , 2001, Advanced drug delivery reviews.

[15]  Tomi Järvinen,et al.  Ocular absorption following topical delivery , 1995 .

[16]  A. Bazarbachi,et al.  Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. , 2006, American journal of ophthalmology.

[17]  K. Kontturi,et al.  Estimation of Pore Size and Pore Density of Biomembranes from Permeability Measurements of Polyethylene Glycols using an Effusion-like Approach , 1997 .

[18]  E. Toropainen,et al.  Cell culture models of the ocular barriers. , 2005, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[19]  A. Urtti,et al.  Minimizing systemic absorption of topically administered ophthalmic drugs. , 1993, Survey of ophthalmology.